Y-mAbs (YMAB) Q2 Revenue Falls 14%
Y-mAbs Therapeutics (NASDAQ:YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The company beat expectations on both revenue and earnings per share, posting GAAP revenue of $19.5 million against a GAAP consensus of $18.4 million, and GAAP EPS of ($0.07) compared to an analyst estimate of ($0.26). However, revenue dropped 14% from the prior year, mainly due to lower product sales. The quarter showed better-than-expected headline financials, but underlying results highlighted ongoing sales pressures and continued reliance on the company’s core product, DANYELZA.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Y-mAbs Therapeutics develops and commercializes immunotherapies for cancer. Its main focus is on antibody-based products, including its core commercial product, DANYELZA, which is used to treat GD2-positive tumors in pediatric neuroblastoma patients. DANYELZA is currently the company’s only approved drug and accounts for nearly all product revenue.
Source Fool.com
